4D Molecular Therapeutics Inc’s filing revealed that its Chief Legal Officer Bizily Scott unloaded Company’s shares for reported $0.26 million on Apr 01 ’24. In the deal valued at $31.78 per share,8,153 shares were sold. As a result of this transaction, Bizily Scott now holds 1,737 shares worth roughly $45596.25.
Then, Bizily Scott sold 5,833 shares, generating $204,410 in total proceeds. Upon selling the shares at $35.04, the Chief Legal Officer now owns 1,737 shares.
Before that, Bizily Scott sold 1,750 shares. 4D Molecular Therapeutics Inc shares valued at $54,722 were divested by the Chief Legal Officer at a price of $31.27 per share. As a result of the transaction, Bizily Scott now holds 1,737 shares, worth roughly $45596.25.
Barclays initiated its 4D Molecular Therapeutics Inc [FDMT] rating to an Overweight in a research note published on April 15, 2024; the price target was $459. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in mid April with a ‘”an Overweight”‘ rating. RBC Capital Mkts started covering the stock on October 26, 2023. It rated FDMT as “an Outperform”.
Price Performance Review of FDMT
On Monday, 4D Molecular Therapeutics Inc [NASDAQ:FDMT] saw its stock fall -0.38% to $26.25. Over the last five days, the stock has lost -8.70%. 4D Molecular Therapeutics Inc shares have risen nearly 29.57% since the year began. Nevertheless, the stocks have risen 55.79% over the past one year. While a 52-week high of $36.25 was reached on 03/27/24, a 52-week low of $9.44 was recorded on 01/19/24. SMA at 50 days reached $29.01, while 200 days put it at $18.90. A total of 0.61 million shares were traded, compared to the trading of 0.65 million shares in the previous session.
Levels Of Support And Resistance For FDMT Stock
The 24-hour chart illustrates a support level at 25.32, which if violated will result in even more drops to 24.38. On the upside, there is a resistance level at 27.81. A further resistance level may holdings at 29.36. The Relative Strength Index (RSI) on the 14-day chart is 39.60, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.61%. Stochastics %K at 10.28% indicates the stock is a buying.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $32 price target.
